Table of Contents Author Guidelines Submit a Manuscript
Prostate Cancer
Volume 2016, Article ID 9462975, 11 pages
http://dx.doi.org/10.1155/2016/9462975
Review Article

Fortifying the Treatment of Prostate Cancer with Physical Activity

1Department of Radiation Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA 15215, USA
2Department of Integrative Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA 15232, USA
3Department of Medical Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA 15232, USA
4Department of Radiation Oncology, Leopoldina Hospital, 97422 Schweinfurt, Germany
5Relentless Fitness, Philadelphia, PA 19106, USA

Received 1 October 2015; Revised 6 January 2016; Accepted 11 January 2016

Academic Editor: Luc Beaulieu

Copyright © 2016 Colin E. Champ et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. V. Pilepich, K. Winter, C. A. Lawton et al., “Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—long-term results of phase III RTOG 85-31,” International Journal of Radiation Oncology Biology Physics, vol. 61, no. 5, pp. 1285–1290, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Bolla, D. Gonzalez, P. Warde et al., “Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin,” The New England Journal of Medicine, vol. 337, no. 5, pp. 295–300, 1997. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Roach III, J. Lu, M. V. Pilepich et al., “Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials,” International Journal of Radiation Oncology Biology Physics, vol. 47, no. 3, pp. 617–627, 2000. View at Publisher · View at Google Scholar · View at Scopus
  4. A. V. D'Amico, M.-H. Chen, A. A. Renshaw, M. Loffredo, and P. W. Kantoff, “Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial,” The Journal of the American Medical Association, vol. 299, no. 3, pp. 289–295, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. W. P. Harris, E. A. Mostaghel, P. S. Nelson, and B. Montgomery, “Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion,” Nature Clinical Practice Urology, vol. 6, no. 2, pp. 76–85, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. J. A. Efstathiou, K. Bae, W. U. Shipley et al., “Obesity and mortality in men with locally advanced prostate cancer: analysis of RTOG 85-31,” Cancer, vol. 110, no. 12, pp. 2691–2699, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Rodriguez, A. V. Patel, E. E. Calle, E. J. Jacobs, A. Chao, and M. J. Thun, “Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States,” Cancer Epidemiology Biomarkers and Prevention, vol. 10, no. 4, pp. 345–353, 2001. View at Google Scholar · View at Scopus
  8. Z. Gong, I. Agalliu, D. W. Lin, J. L. Stanford, and A. R. Kristal, “Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men,” Cancer, vol. 109, no. 6, pp. 1192–1202, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. Y. Cao and J. Ma, “Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis,” Cancer Prevention Research, vol. 4, no. 4, pp. 486–501, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. J. B. Meigs, P. W. F. Wilson, C. S. Fox et al., “Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 8, pp. 2906–2912, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. R. H. Eckel, S. M. Grundy, and P. Z. Zimmet, “The metabolic syndrome,” The Lancet, vol. 365, no. 9468, pp. 1415–1428, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. R. J. Klement and C. E. Champ, “Calories, carbohydrates, and cancer therapy with radiation: exploiting the five R's through dietary manipulation,” Cancer and Metastasis Reviews, vol. 33, no. 1, pp. 217–229, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. S. J. Freedland and W. J. Aronson, “Examining the relationship between obesity and prostate cancer,” Reviews in Urology, vol. 6, no. 2, pp. 73–81, 2004. View at Google Scholar
  14. C. L. Amling, R. H. Riffenburgh, L. Sun et al., “Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy,” Journal of Clinical Oncology, vol. 22, no. 3, pp. 439–445, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. S. J. Freedland, W. J. Aronson, C. J. Kane et al., “Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the shared equal access regional cancer hospital database study group,” Journal of Clinical Oncology, vol. 22, no. 3, pp. 446–453, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. A. R. Shuldiner, R. Yang, and D.-W. Gong, “Resistin, obesity, and insulin resistance—the emerging role of the adipocyte as an endocrine organ,” The New England Journal of Medicine, vol. 345, no. 18, pp. 1345–1346, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. C. E. Champ, J. S. Volek, J. Siglin, L. Jin, and N. L. Simone, “Weight gain, metabolic syndrome, and breast cancer recurrence: are dietary recommendations supported by the data?” International Journal of Breast Cancer, vol. 2012, Article ID 506868, 9 pages, 2012. View at Publisher · View at Google Scholar
  18. I. Janssen, P. T. Katzmarzyk, and R. Ross, “Waist circumference and not body mass index explains obesity-related health risk,” The American Journal of Clinical Nutrition, vol. 79, no. 3, pp. 379–384, 2004. View at Google Scholar · View at Scopus
  19. V. Mohamed-Ali, S. Goodrick, A. Rawesh et al., “Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-α, in vivo,” Journal of Clinical Endocrinology and Metabolism, vol. 82, no. 12, pp. 4196–4200, 1997. View at Google Scholar · View at Scopus
  20. M. A. Rivas, R. P. Carnevale, C. J. Proietti et al., “TNFα acting on TNFR1 promotes breast cancer growth via p42/P44 MAPK, JNK, Akt and NF-κB-dependent pathways,” Experimental Cell Research, vol. 314, no. 3, pp. 509–529, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. V. Michalaki, K. Syrigos, P. Charles, and J. Waxman, “Serum levels of IL-6 and TNF-α correlate with clinicopathological features and patient survival in patients with prostate cancer,” British Journal of Cancer, vol. 90, no. 12, pp. 2312–2316, 2004. View at Google Scholar · View at Scopus
  22. H. S. Park, J. Y. Park, and R. Yu, “Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-α and IL-6,” Diabetes Research and Clinical Practice, vol. 69, no. 1, pp. 29–35, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. P. A. McArdle, K. Mir, A. S. K. Almushatat, A. M. Wallace, M. A. Underwood, and D. C. McMillan, “Systemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer,” Urologia Internationalis, vol. 77, no. 2, pp. 127–129, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. J. L. Ryan, J. K. Carroll, E. P. Ryan, K. M. Mustian, K. Fiscella, and G. R. Morrow, “Mechanisms of cancer-related fatigue,” Oncologist, vol. 12, supplement 1, pp. 22–34, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. D. B. Greenberg, J. L. Gray, C. M. Mannix, S. Eisenthal, and M. Carey, “Treatment-related fatigue and serum interleukin-1 levels in patients during external beam irradiation for prostate cancer,” Journal of Pain and Symptom Management, vol. 8, no. 4, pp. 196–200, 1993. View at Publisher · View at Google Scholar · View at Scopus
  26. K. H. Schmitz, M. L. Neuhouser, T. Agurs-Collins et al., “Impact of obesity on cancer survivorship and the potential relevance of race and ethnicity,” Journal of the National Cancer Institute, vol. 105, no. 18, pp. 1344–1354, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. C. M. Steppan, S. T. Bailey, S. Bhat et al., “The hormone resistin links obesity to diabetes,” Nature, vol. 409, no. 6818, pp. 307–312, 2001. View at Publisher · View at Google Scholar · View at Scopus
  28. G. Boden, “Role of fatty acids in the pathogenesis of insulin resistance and NIDDM,” Diabetes, vol. 46, no. 1, pp. 3–10, 1997. View at Publisher · View at Google Scholar · View at Scopus
  29. V. Venkateswaran, A. Q. Haddad, N. E. Fleshner et al., “Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts,” Journal of the National Cancer Institute, vol. 99, no. 23, pp. 1793–1800, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. R. Root-Bernstein and J. Vonck, “Glucose binds to the insulin receptor affecting the mutual affinity of insulin and its receptor,” Cellular and Molecular Life Sciences, vol. 66, no. 16, pp. 2721–2732, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Beauregard, A.-C. Blouin, V. Fradet et al., “FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy,” Cancer Imaging, vol. 15, article 2, 2015. View at Publisher · View at Google Scholar
  32. S. Djiogue, A. H. N. Kamdje, L. Vecchio et al., “Insulin resistance and cancer: the role of insulin and IGFs,” Endocrine Related Cancer, vol. 20, no. 1, pp. R1–R17, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. C. E. Champ, R. Baserga, M. V. Mishra et al., “Nutrient restriction and radiation therapy for cancer treatment: when less is more,” Oncologist, vol. 18, no. 1, pp. 97–103, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Iwamura, P. M. Sluss, J. B. Casamento, and A. T. K. Cockett, “Insulin-Like growth factor I: action and receptor characterization in human prostate cancer cell lines,” Prostate, vol. 22, no. 3, pp. 243–252, 1993. View at Publisher · View at Google Scholar · View at Scopus
  35. J.-P. Thissen, J.-M. Ketelslegers, and L. E. Underwood, “Nutritional regulation of the insulin-like growth factors,” Endocrine Reviews, vol. 15, no. 1, pp. 80–101, 1994. View at Publisher · View at Google Scholar · View at Scopus
  36. Y. Du, Q. Long, Y. Shi et al., “Insulin-like growth factor binding protein-3 mediates interleukin-24-induced apoptosis through inhibition of the mTOR pathway in prostate cancer,” Oncology Reports, pp. 2273–2281, 2015. View at Publisher · View at Google Scholar
  37. H. Rundqvist, M. Augsten, A. Strömberg et al., “Effect of acute exercise on prostate cancer cell growth,” PLoS ONE, vol. 8, no. 7, Article ID e67579, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Y. Nam, E. J. Lee, K. R. Kim et al., “Effect of obesity on total and free insulin-like growth factor (IGF)-1, and their relationship to IGF-binding protein (BP)-1, IGFBP-2, IGFBP-3, insulin, and growth hormone,” International Journal of Obesity, vol. 21, no. 5, pp. 355–359, 1997. View at Publisher · View at Google Scholar · View at Scopus
  39. R. Kaaks and P. Stattin, “Obesity, endogenous hormone metabolism, and prostate cancer risk: a conundrum of ‘highs’ and ‘lows’,” Cancer Prevention Research, vol. 3, no. 3, pp. 259–262, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. S. A. Kenfield, M. J. Stampfer, E. Giovannucci, and J. M. Chan, “Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study,” Journal of Clinical Oncology, vol. 29, no. 6, pp. 726–732, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. E. L. Richman, S. A. Kenfield, M. J. Stampfer, A. Paciorek, P. R. Carroll, and J. M. Chan, “Physical activity after diagnosis and risk of prostate cancer progression: data from the cancer of the prostate strategic urologic research endeavor,” Cancer Research, vol. 71, no. 11, pp. 3889–3895, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. S. E. Bonn, A. Sjölander, Y. T. Lagerros et al., “Physical activity and survival among men diagnosed with prostate cancer,” Cancer Epidemiology Biomarkers and Prevention, vol. 24, no. 1, pp. 57–64, 2015. View at Publisher · View at Google Scholar · View at Scopus
  43. W. C. Miller, D. M. Koceja, and E. J. Hamilton, “A meta-analysis of the past 25 years of weight loss research using diet, exercise or diet plus exercise intervention,” International Journal of Obesity, vol. 21, no. 10, pp. 941–947, 1997. View at Publisher · View at Google Scholar · View at Scopus
  44. C. C. Curioni and P. M. Lourenço, “Long-term weight loss after diet and exercise: a systematic review,” International Journal of Obesity, vol. 29, no. 10, pp. 1168–1174, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. J. T. Devlin and E. S. Horton, “Effects of prior high-intensity exercise on glucose metabolism in normal and insulin-resistant men,” Diabetes, vol. 34, no. 10, pp. 973–979, 1985. View at Publisher · View at Google Scholar · View at Scopus
  46. S. A. Newsom, A. C. Everett, A. Hinko, and J. F. Horowitz, “A single session of low-intensity exercise is sufficient to enhance insulin sensitivity into the next day in obese adults,” Diabetes Care, vol. 36, no. 9, pp. 2516–2522, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. J. A. Romijn, E. F. Coyle, L. S. Sidossis et al., “Regulation of endogenous fat and carbohydrate metabolism in relation to exercise intensity and duration,” The American Journal of Physiology—Endocrinology and Metabolism, vol. 265, no. 3, pp. E380–E391, 1993. View at Google Scholar · View at Scopus
  48. N. Gao, Z. Zhang, B.-H. Jiang, and X. Shi, “Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer,” Biochemical and Biophysical Research Communications, vol. 310, no. 4, pp. 1124–1132, 2003. View at Publisher · View at Google Scholar · View at Scopus
  49. K. E. O'Reilly, F. Rojo, Q.-B. She et al., “mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt,” Cancer Research, vol. 66, no. 3, pp. 1500–1508, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. Z.-P. Chen, T. J. Stephens, S. Murthy et al., “Effect of exercise intensity on skeletal muscle AMPK signaling in humans,” Diabetes, vol. 52, no. 9, pp. 2205–2212, 2003. View at Publisher · View at Google Scholar · View at Scopus
  51. D. Vavvas, A. Apazidis, A. K. Saha et al., “Contraction-induced changes in acetyl-CoA carboxylase and 5′-AMP- activated kinase in skeletal muscle,” The Journal of Biological Chemistry, vol. 272, no. 20, pp. 13255–13261, 1997. View at Publisher · View at Google Scholar · View at Scopus
  52. J. N. Nielsen, K. J. W. Mustard, D. A. Graham et al., “5′-AMP-activated protein kinase activity and subunit expression in exercise-trained human skeletal muscle,” Journal of Applied Physiology, vol. 94, no. 2, pp. 631–641, 2003. View at Publisher · View at Google Scholar · View at Scopus
  53. R. Bergeron, R. R. Russell III, L. H. Young et al., “Effect of AMPK activation on muscle glucose metabolism in conscious rats,” The American Journal of Physiology—Endocrinology and Metabolism, vol. 276, no. 5, pp. E938–E944, 1999. View at Google Scholar · View at Scopus
  54. R. R. Russell III, R. Bergeron, G. I. Shulman, and L. H. Young, “Translocation of myocardial GLUT-4 and increased glucose uptake through activation of AMPK by AICAR,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 277, no. 2, pp. H643–H649, 1999. View at Google Scholar · View at Scopus
  55. L. W. Jones, B. L. Viglianti, J. A. Tashjian et al., “Effect of aerobic exercise on tumor physiology in an animal model of human breast cancer,” Journal of Applied Physiology, vol. 108, no. 2, pp. 343–348, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. K. A. Simpson and M. A. F. Singh, “Effects of exercise on adiponectin: a systematic review,” Obesity, vol. 16, no. 2, pp. 241–256, 2008. View at Publisher · View at Google Scholar · View at Scopus
  57. M. Zakikhani, R. J. O. Dowling, N. Sonenberg, and M. N. Pollak, “The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase,” Cancer Prevention Research, vol. 1, no. 5, pp. 369–375, 2008. View at Publisher · View at Google Scholar · View at Scopus
  58. C.-H. Tang and M.-E. Lu, “Adiponectin increases motility of human prostate cancer cells via AdipoR, p38, AMPK, and NF-κB pathways,” Prostate, vol. 69, no. 16, pp. 1781–1789, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. J. R. Rider, M. Fiorentino, R. Kelly et al., “Tumor expression of adiponectin receptor 2 and lethal prostate cancer,” Carcinogenesis, vol. 36, no. 6, pp. 639–647, 2015. View at Publisher · View at Google Scholar
  60. B. Faubert, G. Boily, S. Izreig et al., “AMPK is a negative regulator of the warburg effect and suppresses tumor growth in vivo,” Cell Metabolism, vol. 17, no. 1, pp. 113–124, 2013. View at Publisher · View at Google Scholar · View at Scopus
  61. H. Harada, S. Itasaka, S. Kizaka-Kondoh et al., “The Akt/mTOR pathway assures the synthesis of HIF-1α protein in a glucose- and reoxygenation-dependent manner in irradiated tumors,” The Journal of Biological Chemistry, vol. 284, no. 8, pp. 5332–5342, 2009. View at Publisher · View at Google Scholar · View at Scopus
  62. Y. Storozhuk, S. N. Hopmans, T. Sanli et al., “Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK,” British Journal of Cancer, vol. 108, no. 10, pp. 2021–2032, 2013. View at Publisher · View at Google Scholar · View at Scopus
  63. K. Nowak, H. Eldredge-Hindy, and C. Champ, “Metformin: the sweet link between tumor genetics and metabolism?” OA Cancer, vol. 2, no. 1, p. 7, 2014, http://www.oapublishinglondon.com/article/1298. View at Google Scholar
  64. V. E. Zannella, D. Cojocari, S. Hilgendorf et al., “AMPK regulates metabolism and survival in response to ionizing radiation,” Radiotherapy and Oncology, vol. 99, no. 3, pp. 293–299, 2011. View at Publisher · View at Google Scholar · View at Scopus
  65. T. Sanli, A. Rashid, C. Liu et al., “Ionizing radiation activates AMP-activated kinase (AMPK): a target for radiosensitization of human cancer cells,” International Journal of Radiation Oncology Biology Physics, vol. 78, no. 1, pp. 221–229, 2010. View at Publisher · View at Google Scholar · View at Scopus
  66. M. Ristow, M. F. Pfister, A. J. Yee et al., “Frataxin activates mitochondrial energy conversion and oxidative phosphorylation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 22, pp. 12239–12243, 2000. View at Publisher · View at Google Scholar · View at Scopus
  67. T. J. Schulz, R. Thierbach, A. Voigt et al., “Induction of oxidative metabolism by mitochondrial frataxin inhibits cancer growth: Otto Warburg revisited,” The Journal of Biological Chemistry, vol. 281, no. 2, pp. 977–981, 2006. View at Publisher · View at Google Scholar · View at Scopus
  68. G. R. Steinberg and B. E. Kemp, “AMPK in health and disease,” Physiological Reviews, vol. 89, no. 3, pp. 1025–1078, 2009. View at Publisher · View at Google Scholar · View at Scopus
  69. B. K. Pedersen, “Muscles and their myokines,” Journal of Experimental Biology, vol. 214, no. 2, pp. 337–346, 2011. View at Publisher · View at Google Scholar · View at Scopus
  70. N. Mathur and B. K. Pedersen, “Exercise as a mean to control low-grade systemic inflammation,” Mediators of Inflammation, vol. 2008, Article ID 109502, 6 pages, 2008. View at Publisher · View at Google Scholar · View at Scopus
  71. C. Keller, A. Steensberg, H. Pilegaard et al., “Transcriptional activation of the IL-6 gene in human contracting skeletal muscle: influence of muscle glycogen content,” The FASEB Journal, vol. 15, no. 14, pp. 2748–2750, 2001. View at Google Scholar · View at Scopus
  72. B. K. Pedersen, A. Steensberg, P. Keller et al., “Muscle-derived interleukin-6: lipolytic, anti-inflammatory and immune regulatory effects,” Pflugers Archiv European Journal of Physiology, vol. 446, no. 1, pp. 9–16, 2003. View at Publisher · View at Google Scholar · View at Scopus
  73. L. J. Wood, L. M. Nail, and K. A. Winters, “Does muscle-derived interleukin-6 mediate some of the beneficial effects of exercise on cancer treatment-related fatigue?” Oncology Nursing Forum, vol. 36, no. 5, pp. 519–524, 2009. View at Publisher · View at Google Scholar · View at Scopus
  74. T. G. Heck, C. M. Schöler, and P. I. H. de Bittencourt, “HSP70 expression: does it a novel fatigue signalling factor from immune system to the brain?” Cell Biochemistry and Function, vol. 29, no. 3, pp. 215–226, 2011. View at Publisher · View at Google Scholar · View at Scopus
  75. O. Neubauer, D. König, and K.-H. Wagner, “Recovery after an Ironman triathlon: sustained inflammatory responses and muscular stress,” European Journal of Applied Physiology, vol. 104, no. 3, pp. 417–426, 2008. View at Publisher · View at Google Scholar · View at Scopus
  76. M. Kelly, M.-S. Gauthier, A. K. Saha, and N. B. Ruderman, “Activation of AMP-activated protein kinase by interleukin-6 in rat skeletal muscle: association with changes in cAMP, energy state, and endogenous fuel mobilization,” Diabetes, vol. 58, no. 9, pp. 1953–1960, 2009. View at Publisher · View at Google Scholar · View at Scopus
  77. G. van Hall, A. Steensberg, M. Sacchetti et al., “Interleukin-6 stimulates lipolysis and fat oxidation in humans,” The Journal of Clinical Endocrinology & Metabolism, vol. 88, no. 7, pp. 3005–3010, 2003. View at Publisher · View at Google Scholar
  78. P. Rasmussen, P. Brassard, H. Adser et al., “Evidence for a release of brain-derived neurotrophic factor from the brain during exercise,” Experimental Physiology, vol. 94, no. 10, pp. 1062–1069, 2009. View at Publisher · View at Google Scholar · View at Scopus
  79. R. Chen, F. X. Liang, J. Moriya et al., “Chronic fatigue syndrome and the central nervous system,” Journal of International Medical Research, vol. 36, no. 5, pp. 867–874, 2008. View at Publisher · View at Google Scholar · View at Scopus
  80. R. J. Segal, R. D. Reid, K. S. Courneya et al., “Resistance exercise in men receiving androgen deprivation therapy for prostate cancer,” Journal of Clinical Oncology, vol. 21, no. 9, pp. 1653–1659, 2003. View at Publisher · View at Google Scholar · View at Scopus
  81. L. Bourke, S. Gilbert, R. Hooper et al., “Lifestyle changes for improving disease-specific quality of life in sedentary men on long-term androgen-deprivation therapy for advanced prostate cancer: a randomised controlled trial,” European Urology, vol. 65, no. 5, pp. 865–872, 2014. View at Publisher · View at Google Scholar · View at Scopus
  82. D. A. Galvão, N. Spry, J. Denham et al., “A multicentre year-long randomised controlled trial of exercise training targeting physical functioning in men with prostate cancer previously treated with androgen suppression and radiation from TROG 03.04 radar,” European Urology, vol. 65, no. 5, pp. 856–864, 2014. View at Publisher · View at Google Scholar · View at Scopus
  83. P. Cormie, D. A. Galvão, N. Spry et al., “Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial,” BJU International, vol. 115, no. 2, pp. 256–266, 2015. View at Publisher · View at Google Scholar · View at Scopus
  84. R. J. Segal, R. D. Reid, K. S. Courneya et al., “Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer,” Journal of Clinical Oncology, vol. 27, no. 3, pp. 344–351, 2009. View at Publisher · View at Google Scholar · View at Scopus
  85. U. Monga, S. L. Garber, J. Thornby et al., “Exercise prevents fatigue and improves quality of life in prostate cancer patients undergoing radiotherapy,” Archives of Physical Medicine and Rehabilitation, vol. 88, no. 11, pp. 1416–1422, 2007. View at Publisher · View at Google Scholar · View at Scopus
  86. P. L. Nguyen, M.-H. Chen, C. J. Beard et al., “Radiation with or without 6 months of androgen suppression therapy in intermediate- and high-risk clinically localized prostate cancer: a postrandomization analysis by risk group,” International Journal of Radiation Oncology Biology Physics, vol. 77, no. 4, pp. 1046–1052, 2010. View at Publisher · View at Google Scholar · View at Scopus
  87. N. L. Keating, A. J. O'Malley, and M. R. Smith, “Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer,” Journal of Clinical Oncology, vol. 24, no. 27, pp. 4448–4456, 2006. View at Publisher · View at Google Scholar · View at Scopus
  88. A. W. Hsing, Y.-T. Gao, S. Chua Jr., J. Deng, and F. Z. Stanczyk, “Insulin resistance and prostate cancer risk,” Journal of the National Cancer Institute, vol. 95, no. 1, pp. 67–71, 2003. View at Publisher · View at Google Scholar · View at Scopus
  89. S. Lehrer, E. J. Diamond, S. Stagger, N. N. Stone, and R. G. Stock, “Increased serum insulin associated with increased risk of prostate cancer recurrence,” Prostate, vol. 50, no. 1, pp. 1–3, 2002. View at Publisher · View at Google Scholar · View at Scopus
  90. J. R. Gardner, P. M. Livingston, and S. F. Fraser, “Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: a systematic review,” Journal of Clinical Oncology, vol. 32, no. 4, pp. 335–346, 2014. View at Publisher · View at Google Scholar · View at Scopus
  91. T. S. Nilsen, T. Raastad, E. Skovlund et al., “Effects of strength training on body composition, physical functioning, and quality of life in prostate cancer patients during androgen deprivation therapy,” Acta Oncologica, vol. 54, no. 10, pp. 1805–1813, 2015. View at Publisher · View at Google Scholar
  92. J. M. Harrington, D. C. Schwenke, and D. R. Epstein, “Exercise preferences among men with prostate cancer receiving androgen-deprivation therapy,” Oncology Nursing Forum, vol. 40, no. 5, pp. E358–E367, 2013. View at Publisher · View at Google Scholar · View at Scopus
  93. M. R. Harrison and L. W. Jones, “Exercise as treatment for androgen deprivation therapy-associated physical dysfunction: ready for prime time?” European Urology, vol. 65, no. 5, pp. 873–874, 2014. View at Publisher · View at Google Scholar · View at Scopus
  94. P. Ekkekakis, E. E. Hall, and S. J. Petruzzello, “Some like it vigorous: measuring individual differences in the preference for and tolerance of exercise intensity,” Journal of Sport & Exercise Psychology, vol. 27, no. 3, pp. 350–374, 2005. View at Google Scholar · View at Scopus
  95. F. T. Baumann, E. M. Zopf, and W. Bloch, “Clinical exercise interventions in prostate cancer patients-a systematic review of randomized controlled trials,” Supportive Care in Cancer, vol. 20, no. 2, pp. 221–233, 2012. View at Publisher · View at Google Scholar · View at Scopus
  96. T. H. Lee, Ed., Calories Burned in 30 Minutes for People of Three Different Weights—Harvard Health, Harvard Health Publications, 2004, http://www.health.harvard.edu.